Venture capital funding isn’t what it used to be for medical device startups, but there are actually reasons to feel optimistic about medtech funding.

That was the big takeaway from a four-expert panel at DeviceTalks Minnesota last month. (The next DeviceTalks is Oct. 2 in Boston.)

Charlie Whelan, director of transformational health consulting at Frost & Sullivan, led a discussion with Anne Sissel, managing director for Baxter Ventures; Kathleen Tune, an advisor at Thomas, McNerney & Partners; and Dr. Dennis Wahr, president and CEO of Nuvaira.

Here are five important insights that came out of the discussion.

Next>>

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]